High materiality7/10
MapLight Therapeutics price target lowered to $21 from $24 at Canaccord
Why it may matterVerify against the original reporting
Notable upside potential ahead; favorable target vs price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Canaccord Genuity lowers MPLT target to $21; current price around $11.63. Indicates meaningful upside potential.
- Target $21 vs price $11.63; Canaccord Genuity.
Key facts
- 01
Target: $21
- 02
Posted price: $11.63
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: Sumant Kulkarni
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.